Pharmacogenomic testing in depression a review of clinical effectiveness, cost-effectiveness, and guidelines
The purpose of this report is to examine the clinical effectiveness, cost-effectiveness of pharmacogenomic testing versus treatment as usual for treating all severities of diagnosed depression. Additionally, evidence-based guidelines regarding the pharmacogenomic testing in patients with all severit...
| Main Authors: | , |
|---|---|
| Corporate Author: | |
| Format: | eBook |
| Language: | English |
| Published: |
Ottawa
Canadian Agency for Drugs and Technologies in Health
2020, January 31, 2020
|
| Edition: | Version: 1.0 |
| Series: | CADTH rapid response report: summary with critical appraisal
|
| Subjects: | |
| Online Access: | |
| Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
| Summary: | The purpose of this report is to examine the clinical effectiveness, cost-effectiveness of pharmacogenomic testing versus treatment as usual for treating all severities of diagnosed depression. Additionally, evidence-based guidelines regarding the pharmacogenomic testing in patients with all severities of diagnosed depression will be reviewed |
|---|---|
| Physical Description: | 1 PDF file (38 pages) illustrations |